Abstract | Susceptibility to rheumatic diseases, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, juvenile idiopathic arthritis and psoriatic arthritis, includes a large genetic component. Understanding how an individual's genetic background influences disease onset and outcome can lead to a better understanding of disease biology, improved diagnosis and treatment, and, ultimately, to disease prevention or cure. The past decade has seen great progress in the identification of genetic variants that influence the risk of rheumatic diseases. The challenging task of unravelling the function of these variants is ongoing. In this Review, the major insights from genetic studies, gained from advances in technology, bioinformatics and study design, are discussed in the context of rheumatic disease. In addition, pivotal genetic studies in the main rheumatic diseases are highlighted, with insights into how these studies have changed the way we view these conditions in terms of disease overlap, pathways of disease and potential new therapeutic targets. Finally, the limitations of genetic studies, gaps in our knowledge and ways in which current genetic knowledge can be fully translated into clinical benefit are examined.
The major rheumatic diseases, including osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondy litis (AS), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA), have multiple genetic and environmental risk factors involved in disease onset. Susceptibility to all these dis eases is attributable largely to the genomic background of patients [1] [2] [3] [4] [5] , with heritability estimates ranging from 50% in OA 5 to >90% in PsA 3 . This genomic susceptibility outweighs the combined risk arising from environmen tal factors, such as smoking, diet, environment, infection and occupation [1] [2] [3] [4] [5] . Genetic susceptibility is therefore a fundamental aspect of rheumatic diseases, and a full understand ing of how genetic variants influence disease processes has the potential to influence disease management. No single genetic risk factor is essential for disease devel opment; rather, combinations of multiple variants influence not only susceptibility to disease, but also the disease course or outcome, as well as response to therapy. Indeed, heterogeneity, in terms of both disease presentation and outcome, presents a key challenge to rheumatologists. Genetics provides an opportunity to address this heterogeneity through classifying patients into more homogeneous subtypes based on the genetic pathways that drive disease. This stratification will ena ble clinicians to target therapy to those patients most likely to respond. Effectively treating disease early on is key to improving longterm outcomes for patients and the eventual development of predictive algorithms might enable identification of diseasesusceptible indi viduals and perhaps ultimately lead to disease pre vention. In addition, genetics can affect therapeutic management. Determining which genes and pathways are implicated in a disease provides the opportunity to reposition therapies that successfully target the same pathways in other diseases, or to revisit therapies that have previously failed in clinical trials of unselected patients but might have therapeutic benefit in a subset of patients. In the past 2 years, data indicate that novel therapies targeting pathways whose role in disease is backed by genetic evidence are twice as likely to pro gress through a pharmaceutical pipeline and deliver a new drug than those without any genetic evidence 6 , with obvious financial implications.
Arguably, the modern era of genetic research in rheu matic diseases began in 2007 with the Wellcome Trust Case Control Consortium (WTCCC) study 7 ( FIG. 1; TABLE 1). The WTCCC recognized that common vari ants with low effect sizes that increase risk to common 1 
Single nucleotide polymorphism (SNP)
DNA sequence variation of a single nucleotide that occurs at a specific position in the genome.
Candidate gene
In genetic association studies, the candidate gene approach tests associations between genetic variation within pre-specified genes of interest and phenotypes.
Genome-wide significance threshold P value threshold that is considered statistically significant after multiple testing correction in GWAS, typically P <5 × 10 −8 .
Non-synonymous SNPs
SNPs that map to coding genes and result in an amino acid change in the protein they encode.
diseases would only be detected by using large sam ple sizes, collected through collaborative efforts. The WTCCC study now seems relatively lowpowered in comparison with some of the metaanalysis genome wide association studies (GWAS) utilizing many 10,000s to 100,000s of samples that have been performed sub sequently, but at the time, it introduced a paradigm shift in the genetic research of complex diseases. The study 7 compared 14,000 patients who had one of seven diseases (rheumatic diseases represented by RA) with 3,000 controls. The use of highdensity single nucleotide polymorphism (SNP) arrays revealed genomewide asso ciations for each disease. The WTCCC study was a step forward in genomic research, as previous attempts to link genetic changes to disease development were either largely based on lowpowered family linkage studies, or were candidate gene studies that assessed disease asso ciations one gene at a time. The success of the WTCCC study was dependent on not only its scale, but also on its use of genetic mapping and other technological advances that happened concurrently.
A SNP is generally accepted to be robustly associ ated with disease in GWAS if the difference in variant (allele) frequency between cases and controls surpasses a genome-wide significance threshold. This threshold is set to account for multiple comparisons, and many variants might not reach genomewide significance, particularly those investigated in early GWAS (which had relatively small sample sizes). Therefore, any putative association requires further validation in independent cohorts of cases and controls. Since the pioneering WTCCC study, many more GWAS have been performed, such that the GWAS Catalog documented over 24,000 unique SNP trait associations (as of August 2016). The story for rheumatic diseases has been one of increasing GWAS sample sizes, leading to the discovery of an increasing number of diseaseassociated variants and providing further insights into disease mechanisms.
In this Review, we provide a discussion of the major insights gained from genetic studies in rheumatic dis eases, such as GWAS, metaanalyses, finemapping and studies performed across different diseases and/or ethnicities. We highlight the most relevant genetic stud ies in the main rheumatic diseases and discuss how they have enhanced our knowledge of these diseases in terms of disease overlap, pathways to disease and poten tial new therapeutic targets. We also examine the first efforts to understand how genetic variants influence disease biology.
GWAS in rheumatic diseases
The year 2007 saw the first real advances in discovering novel genetic associations with RA susceptibility (FIG. 1) . The WTCCC study found two genetic regions associ ated with RA that reached genomewide significance 7 : HLA-DRB1 and PTPN22. GWAS conducted in the USA added TNFAIP3 (REF. 8 ) and the TRAF1-C5 locus 9 to this list. In addition, a candidategene study confirmed an association of STAT4 with RA susceptibility 10 , bring ing the number of loci implicated in RA risk up to five. Further studies in RA, using large international cohorts, validated markers that either had evidence suggestive of an association with RA (that is, reaching a suggestive genomewide significance threshold of P <1 × 10 −6 ) or variants identified with statistical text mining meth ods (such as gene relationships across implicated loci; GRAIL), bringing the number of confirmed variants associated with RA up to 31 by 2010 . These variants included those mapped to regions in CTLA4, IL2RA, CCL21 and AFF3. These early GWAS findings in RA confirmed the role of T cell immunity in disease development, something already assumed but now firmly established.
Similar GWAS have investigated the other major rheumatic diseases. For example, one of the first large scale genetic studies in AS, which again involved the WTCCC, focused on 14,500 non-synonymous SNPs in 1,000 patients with AS and 1,500 healthy individuals 15 . This study confirmed the already established link between HLA-B27 and risk of AS, while also implicat ing both ERAP1 and IL23R in disease pathogenesis. In 2011, the most recent GWAS in AS 16 , which used a dis covery cohort of >1,700 patients with AS and a valida tion cohort of ~2,000 patients with AS, confirmed the disease association with these three regions. This study also validated two other associations, in regions located in chromosomes 2 and 21 that had been identified by a previous GWAS 17 , and showed a further seven regions to be associated with AS, including variants within the RUNX3, IL12B, TNFRSF1A and CARD9 loci 16 . A wellpowered GWAS that included ~7,500 patients with OA in the initial screen and similar num bers in a validation cohort provided further insights into the genetics driving OA 18 . This pivotal study brought the number of known loci associated with OA onset from 3 to 11. Epidemiological studies had previ ously demonstrated a heterogeneity of the OA pheno type 19 , and the findings from this GWAS emphasized this heterogeneity; associations were revealed only when the data was stratified into more homogeneous subtypes, for example by site of OA (hip or knee), sex or both. The study also showed an association of OA with the FTO gene, which was previously shown to be important in obesity 20 , reinforcing the link between body weight and OA. 
Statistical power
Probability that a test correctly rejects the null hypothesis.
Risk score
Estimate of the cumulative contribution of genetic factors to a specific outcome of interest in an individual that takes into account the reported risk alleles.
GWAS meta-analyses
The utilization of GWAS around the globe has ena bled the development of largescale metaanalyses of many thousands of samples, collected through inter national collaborations. This increased sample size vastly improves the statistical power of a study to detect diseaseassociated variants and reduces the necessity for individual groups to perform validation studies. However, interpretation of metaanalyses of global populations might still require careful consideration. For example, different frequencies of DNA variants can occur in different populations, potentially resulting in the identification of spurious or inexact associations. This issue can be avoided through the use of a robust study design and sophisticated analytical techniques (such as principal component analysis).
Metaanalyses have been of great use in rheuma tology. For example, a metaanalysis of hip OA GWAS involving >78,000 European participants 21 showed a novel association with a SNP variant that was later shown to correlate with the expression of NCOA3 in cartilage 22 . NCOA3 is a gene linked to the expression of COL2A1, RUNX2 and MMP13 in chondrocytes, which are all important mediators of OA. Another study that combined a GWAS, a metaanalysis and a validation study identified ten new SLEassociated loci, bringing the number of regions robustly associ ated with SLE in Europeans up to 40 (REF. 23 ). This study was the largest genetic study in a European popula tion, and involved over 7,000 participants of European descent. The researchers also identified ten missense coding variants that probably influence the risk of SLE, which were largely present in genes encoding kinases and other enzymes. In addition, the location of sev eral diseaseassociated loci implicated a number of transcription factors in SLE, indicating that regulation of gene expression is likely to have an important role in disease development. Metaanalysis of three GWAS data sets from both Chinese and European populations, which totalled >15,600 samples, revealed a further ten loci associated with SLE, and showed that these risk loci generally overlapped between populations. In this study, the prevalence of SLE in different populations (that is, European, Amerindian, South Asian, East Asian and African populations) was matched by the genetic risk score conferred by the risk alleles 24 . A large international GWAS metaanalysis investi gating RA, involving a consortium from across Europe, the USA and Japan, brought the number of identified RArisk regions up to 101 (REF. 25 ). This multiethnic study revealed extensive sharing of genetic risk loci between Asian and European populations, with only five loci showing a populationspecific association. The study findings also confirmed a strong link between RA and T cell immunity. Further analysis in 34 tissues demon strated an enrichment of RArisk loci in open and active regions of the genome (as defined by epigenetic histone markers) in primary CD4 + T cells 26 . By assigning putative causal genes to these regions, this study demonstrated an enrichment of diseaseassociated loci in signalling path way genes and genes encoding approved RA drug tar gets. A study investigating OA revealed differences in the diseaseassociated variants found in European and Asian cohorts, with only one region, found within GDF5, hav ing an unambiguous shared genetic association between these two populations 27 . The protein encoded by GDF5, growth/differentiation factor 5 (GDF5), is a member of the TGFβ superfamily and is important in chondrogen esis and bone growth. Thus, largescale international metaanalysis of GWAS has the capacity to determine 75 An international collaboration with the goal of building a comprehensive catalogue of all functional elements in the human genome
Given that most GWAS variants map to noncoding regulatory regions of the genome, unravelling the exact function and mechanism of these regulatory elements is essential to unravelling disease biology Human Genome project (HGP) 108 A project designed to sequence the whole human genome
Determined the exact order of the base pairs in the genome, essential for the design of any genetic study
The international HapMap project 109 By mapping all SNPs found in 1,301 individuals drawn from 11 ancestral groups, this project enabled the identification of highly correlated SNPs or haplotypes
HapMap helped reduce the number of SNPs required to examine the entire genome for associations with a particular phenotype. This number was reduced from the 10 million SNPs that exist to roughly 1 million 'tag' SNPs. HapMap's initial efforts have since been greatly expanded; both in number of individuals (tens of thousands) and populations, but they were sufficient to inform early GWAS studies
A group of 50 research groups across the UK that performed the first major GWAS, which included seven common diseases
Through the use of large sample sizes, large collaborative efforts make the detection of SNPs that increase disease risk with low effect sizes possible
Study method
Cross This approach enables large-scale replication in independent populations, cross-population meta-analyses to increase power, prioritization of candidate genes and fine-mapping of functional variants
Validation study 114 The study of a subset of GWAS markers that have passed a set threshold of statistical significance, performed in a population separate from that from which the original sample was drawn Validation studies are essential to confirm GWAS results and eliminate false positives and overestimated effects
Technique
Bayesian methods 115 This method provides an alternative to the usual 'frequentist' approach to assessing associations. The posterior probability for each SNP is calculated based on the assumption that the SNP is driving the association and the evidence for association is measured by the Bayes factor, a statistical index that quantifies the evidence for a hypothesis compared with an alternative hypothesis Bayesian methods compute measures of evidence that can be directly compared among SNPs within and across studies, facilitating meta-analysis. They can also be applied to define credible SNP sets, which improve fine-mapping Genotyping of all known variants in an associated region of DNA in large cohorts of cases and controls
Enables the identification of the variant(s) in a given locus with the greatest evidence for causal association
Linkage disequilibrium
Nonrandom association of alleles at different loci in a given population.
ethnic differences in diseaseassociated variants, and to illuminate these differences in terms of the variants, genes and pathways involved and the gene-environment interactions observed between individuals of different geographical regions and ethnicities.
The high degree of overlap in genetic susceptibility observed across different autoimmune and inflamma tory diseases has led researchers to combine GWAS cohorts for metaanalysis across different diseases as a means to increase the number of susceptibility loci iden tified. A combined analysis of AS and four other clini cally related diseases, including psoriasis, Crohn's disease and ulcerative colitis, used >50,000 patients and 30,000 controls, which increased the power to detect genetic associations shared across these similar diseases and led to the identification of 17 new GWAS loci for AS, bring ing the total number to 48 (REF. 28 ). Pathway analysis followed by a search for genes that encode known drug targets highlighted potential novel therapeutic targets in AS, such as C-C chemokine receptor type 2 (CCR2) and CCR5. Hence the development of the CCR2 and CCR5 antagonists (MLN1202 and AMD070, respectively) as potential novel therapeutics for AS.
Fine-mapping GWAS data
Associations identified following GWAS, validation and metaanalysis will typically implicate multiple genetic variants in disease susceptibility; further genetic stud ies are required to 'finemap' the genetic associations and better define the causal variant. Finemapping involves genotyping large cohorts of cases and controls for all known variants in a diseaseassociated region of DNA to experimentally determine the mostly likely causal variant in that region. As a preceding step, the DNA region can be resequenced using a cohort of either disease specific cases or controls to ensure all variants are included when finemapping. This step is increas ingly less likely to identify novel variants as largescale sequencing projects such as the UK10K Project and the 1000 Genomes Project are continuing to add to the catalogue of known variants in multiple populations, although it could still prove fruitful if the causal variant is as yet undiscovered. For example, in a study of SLE, resequencing identified a single base pair insertion in a region of DNA close to TNFAIP3, which is probably the causal variant for this region's association with SLE 29 .
One of the more surprising findings from the GWAS era was the extent of overlap seen between different autoimmune diseases, including some rheumatic dis eases, in their diseaseassociated DNA regions. This observation led to the development of a common, costeffective genotyping array that included all known genetic variants associated with autoimmune diseases: the Immunochip 30 . The availability of this array enabled largescale, highthroughput genotyping for a whole range of rheumatic diseases. This finemapping approach led to the addition of 13 new genes to the list of those associated with AS suspectibility 31 , including IL6R, IL27 and BACH2, and a similar number for RA 30 . Use of the Immunochip array has also added 13 new JIAassociated loci 32 , including those implicating STAT4, IL2RA and IL2RB, to the three previously confirmed by GWAS (the HLA region, PTPN22 and PTPN2). In a 2011 study of patients with SLE of Asian ancestry, use of this array iden tified 10 new disease associated loci and confirmed 20 others. Interestingly, one of these newly discovered loci, found within the SYNGR1 gene, has a frequency of 80% in Asians but only 20% in Europeans, suggesting natural selection of the gene in Asian populations 33 . Statistical analysis of finemapping data can be employed to determine the number of independent association signals in a given region, the variant(s) most strongly associated with disease (that is, the 'lead' or 'index' SNP) and sets of highly correlated (linkage disequilibrium r 2 >0.9) SNP variants, all of which are equally likely to be causal. Within the last decade, Bayesian meth ods have been employed to finemap disease associated loci [34] [35] [36] . In addition, conditional logistic regression 
• ERAP2
• IRF1
• IL6R analysis -that is, reanalysing the data with the lead sig nal removed -enables further definition of the genetic architecture of a region; for example, this analysis can determine whether multiple signals are present within the region. These approaches have been used to great effect in rheumatic diseases, for which the major susceptibility locus resides within the highly complex and generich HLA region. Highdensity genotyping has been used to identify three independent genetic signals in the class I region of HLA that increase the risk of developing PsA 37 . The availability of large genotyped cohorts enabled one study to better refine the RA associations located within the HLA region 38 , revealing three independent signals in this region. In this analysis, the major disease risk asso ciation was found to arise from a change in the amino acid at position 13, which is located in the major binding groove of HLADR, outside the previously welldefined shared epitope sequence (amino acid positions [70] [71] [72] [73] [74] . Loci residing outside the HLA region have similarly been refined by use of conditional logistic regression analysis 30 .
Overlap between diseases
Genetic analysis can illuminate the genetic similarities between diseases. For example, by use of combined data analysis of multiple seronegative diseases, one study demonstrated that Crohn's disease and inflammatory bowel disease (IBD) share some diseaseassociated loci with AS (20 and 48 loci, respectively) 28 . Other genetic studies have shown the IL17-IL23 pathway to be pivotal in the overlap observed between autoimmune diseases 39 , leading to the idea of repurposing drugs that target this pathway, such as ustekinumab. As shown by statistical analysis, JIA is genetically more similar to type I diabetes mellitus, another juvenileonset auto immune disease, than to other rheumatic diseases 40 . Genes involved in the IL2 pathway, including IL2, IL2RA and IL2RB, drive this overlap. Similarly, genes associated with PsA demonstrate little or no overlap with RAassociated genes, but PsA has an almost complete genetic overlap with psoriasis and strong overlap with IBD 37 . The nature of these overlaps is evident in disease therapy, in which some therapies have shown success in treating psoriasis, PsA and IBD, whereas the highly suc cessful antiTNF biologics developed for RA have shown little efficacy in treating psoriasis or PsA 41 . Extensive GWAS, metaanalyses, Immunochip assays and crossdisease metaanalysis in systemic sclerosis (SSc) have revealed ≤20 nonHLA regions associated with risk of disease 42, 43 , and have confirmed a genetic overlap of this disease with SLE and RA; >70% of SSc associated SNPs are also associated with SLE and 50% with RA. Associations in many genetic regions, includ ing IRF5 and IRF8, are shared across all the major rheu matic diseases, whereas CSK, BANK1 and TNIP1 are associated only with SSc and SLE. A large crossdisease analysis of SSc and RA, involving >8,800 patients with SSc, 16,800 patients with RA and 44,000 controls, showed associations with components of the type I interferon signalling pathway (IRF4, IRF5, IRF8) that were shared across diseases, clearly demonstrating the importance of this pathway in both diseases 44 . Although overlap between inflammatory and autoimmune dis eases might not be surprising, in 2014 the most recent and largest metaanalysis in RA revealed that many disease associated genomic regions are shared with blood cancers, including leukaemia and Hodgkin lymphoma 25 . This finding is suggestive of opportunities to reposition drugs that are successful in treating blood cancers and have already passed expensive and stringent safety and efficacy trials, for the treatment of RA. These drugs include alvocidib and palbociclib, which target both cyclin dependent kinase 4 (CDK4) and CDK6 (whose genes map to regions associated with RA) in lymphomas and leukaemias 45 . (FIG. 2) suggests that disease mechanisms, and hence appropriate treatment choices, also overlap. However, this line of thinking Figure 2 | Overlap of associated loci among five rheumatic diseases. Shared genetic susceptibility loci between rheumatic diseases suggest that these diseases also share biological disease mechanisms and treatment options. This figure illustrates the number of overlapping loci observed between the major rheumatic diseases (for the unnumbered areas the overlap is zero) and highlights some relevant disease-associated genes. Rheumatic diseases with substantial available GWAS, validation and fine-mapping data are included. Key disease-associated genes include PADI4 in rheumatoid arthritis (RA), involved in the citrullination of proteins; anti-citrullinated protein antibodies (ACPA) are a key distinctive component of this disease. CTLA4 and IL6R are targets of the biologic therapies abatacept and tocilizumab, respectively, effective therapies for RA. The association of ITGAM variants with systemic lupus erythematosus (SLE) reinforce the importance of the complement system in this rheumatic disease, whereas the association of LCE3A variants with psoriatic arthritis (PsA) shows the organ-specific and disease-specific nature of some of these genetic associations (in this case, the skin). AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis.
Genetic overlap between diseases
requires careful consideration. Shared associations at a particular locus could be attributable to different poly morphisms, or to the same variant but with different directions of effect; that is, an associated allele could con fer risk for one disease but be protective for another. This difference is exemplified by variants in IL6R (an allele that is protective for RA is a risk allele for asthma) 30, 46 , PTPN22 (certain alleles that are associated with risk of RA, among many other diseases, are protective against Crohn's disease) 47, 48 and SH2B3 (some alleles that are protective against AS are associated with risk of Crohn's disease) 31, 48 . Similarly, one of the most intriguing genetic findings in PsA is that although IL23R is strongly impli cated in both psoriasis and PsA, it is likely that different genetic variants within this region are responsible for the risk association observed in each disease 37 . This finding suggests that the IL23-IL17 pathway is pivotal to both diseases, but that these two diseases have evolved dif ferently; hence, subtle differences in the control of the IL23 pathway, either spatial, temporal or in terms of magnitude, could lead to these different diseases.
Disease pathway analysis
Given the physical proximity of an associated variant to specific genes and biological knowledge of a disease, var iants identified in GWAS can be assigned to a gene, or a number of genes, thought likely to be involved in disease. This process has led to the development of biological 'pathway' analysis, providing intriguing new insights into disease mechanisms. Researchers routinely anno tate biological pathways with information such as the associated protein-protein interactions, coexpressed genes and involved receptors and their antigens. This information is available to researchers in resources such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), the Database for Annotation, Visualisation and Integrated Discovery (DAVID) and Ingenuity Pathway Analysis (IPA) software. By placing implicated genes on preannotated pathways, researchers have used genetic studies to demonstrate a range of immune and non immune pathways that drive rheumatic diseases. Among these pathways, the T helper cell differentiation pathway seems to have a prominent role in the development of RA, JIA, PsA, SLE and AS (FIG. 3) .
The confirmed genes implicated by GWAS in SLE fall into three broad pathways: lymphocyte activation, particularly B cells, which includes the genes BLK, PRDM1, STAT4 and BANK1; innate immunity, particu larly the NFκB and type I interferon pathways, includ ing NFKB1 and IFN1, driven by IRF5, IRAK1, TLR7 and TLR9; and apoptosis, including ATG5 and ITGAM 49, 50 . Similar approaches in AS have demonstrated that gut mucosal immunity is important in disease suscepti bility, with genes identified in GWAS implicating both gut lymphoid tissue (RUNX3, EOMES and ZMIZ1) and bacteriasensing Gproteincoupled receptors (GPR35, GPR37 and GPR65) 51, 52 . Of the 36 nonHLA loci known to be associated with AS, five implicate genes involved in the IL23 signalling pathway, including IL23R, IL12B, TYK2 and IL27, with genes in this pathway representing the overlapping genetic component observed between AS and IBD 31, 48, 53 . Another mechanism implicated in AS is peptide trimming by aminopeptidases, with genetic associations implicating ERAP1, ERAP2 and NPEPPS in disease 53 . In fact, by using conditional logistic regres sion analysis, researchers have shown that ERAP1 is only associated with AS when in the presence of the HLA-B27 allele, a major diseaseassociated variant 31 . Endoplasmic reticulum aminopeptidase 1 (ERAP1) is responsible for trimming peptides to be presented by the HLA protein; thus, this genetic analysis clearly demonstrates that the association between ERAP1 and AS depends on the presentation of processed peptides by the risk associated HLA allele.
Large genetic studies have implicated 14 genes with the onset of OA, including transcription factors (such as RUNX2, SMAD3 and PTHLH) that regulate chondro genesis and endochondral ossification, revealing that it is skeletal development that is important in disease and not the structural proteins themselves 54, 55 . Genetic studies have so far failed to demonstrate any association between inflammatory genes and OA, although evidence from epigenetic studies of some subtypes of OA would suggest an inflammatory component to this disease, with obvious implications for therapeutic targeting 56 . In SSc, the genetic regions implicated in disease sug gest a role for innate immunity (IRF4, IRF8, TNFAIP3, TNIP1) and adaptive immunity (CD247, CSK, PTPN22), while also highlighting the important roles of apoptosis, autophagy and fibrosis in disease (DNASE1L3, ATG5 and PPARG) 42 .
Less-studied rheumatic diseases GWAS have led to an increased understanding of dis eases such as Sjögren syndrome, Paget disease, gout and granulomatosis with polyangiitis (GPA, formerly known as Wegener granulomatosis). Sjögren syndrome can arise as a primary disease, but more often occurs alongside (and shares some clinical features with) other, more common rheumatic diseases, such as SLE and RA. Consequently, the strong overlap observed in GWAS studies between Sjögren syndrome and other rheumatic diseases, particularly SLE, with variants close to IRF5, STAT4, TNFAIP3, and BLK being associated with risk of both SLE and Sjögren syndrome, is not surprising. However, two Sjögrenassociated variants CXCR5 and GTF2I do not show any association with SLE, and hence might distinguish these two diseases 57, 58 . For Paget disease, which is a disease of aberrant bone development, GWAS and family linkage studies have, per haps unsurprisingly, revealed riskassociated genes in the osteoclast differentiation pathway, such as CSF1, RANK (also known as TNFRSF11A), DCSTAMP (also known as TM7SC4) and SQSTM1 (REFS 59, 60) . A gene associated with Paget disease in a GWAS and further explored in sequencing and functional experiments, RIN3, is also thought to be involved in osteoclast development 61 . GWAS have revealed that vasculitic diseases, includ ing GPA, eosinophilic granulomatosis with poly angiitis (EGPA) and microscopic polyangiitis (MPA), have distinct genetic risk variants. GWAS analysis in GPA and MPA have revealed that these two forms of vasculitis differ in terms of HLA associations (HLA-DP and HLA-DQ, respectively), and also implicated addi tional genes such as SERPINA1, PRTN3, COL11A2 and SEMA6A 62, 63 in GPA. SERPINA1 encodes a potent inhib itor of protease 3 (PR3); hence, this genetic association suggests a biological link to the high circulating levels of PR3 observed in many patients with vasculitis. A large scale metaanalysis of all published genetic studies of vasculitis 64 confirmed that different serological subtypes of vasculitis have different genetic backgrounds, and that CTLA4, CD226, STAT4 and IRF5 are also potential risk factors for this disease.
Gout, a disease characterized by dysregulated serum urate concentration, has been the subject of a largescale GWAS analysis. In this study, >140,000 samples from the general population were analysed for serum urate concen tration 65 , and associated risk variants for both high serum urate concentration and gout implicated urate transporter genes, such as SLC2A9, ABCG2, SLC22A11, and the gly colytic pathway gene GCKR. Candidategene approaches have also implicated the NLRP3 inflammasome in development of gout 66 .
Stratified medicine approaches
Defining the genetic risk profile underpinning disease heterogeneity could lead to the development of stratified medicine approaches based on the dysfunction and/or dysregulation of key pathways in different subsets of patients. RA is the most ideally placed rheumatic dis ease to benefit from such approaches. A variety of bio logic therapies are already available that target different pathways containing implicated RAsusceptibility genes, with each therapy currently being effective in approxi mately 40% of patients 67 . For example, variants within the TYK2 gene, a key component of the Janus kinasesignal transducers and activators of transcription (JAK-STAT) signalling pathway, are associated with RA 30 , as well as with JIA 32 , PsA 37 , AS 52 and SLE 24 . Tocilizumab, an IL6 receptor (IL6R) inhibitor, targets this pathway and has demonstrated efficacy in the treatment of RA 68 . A SNP variant that leads to increased cleaving of mem branebound IL6R to its soluble form is associated with RA and mimics the effect of the drug 30, 69 . Importantly, a SNP allele associated with protection from RA 30 and coronary heart disease 70 is associated with risk of asthma 46 . These findings demonstrate how genetic knowledge can provide not only novel therapeutic tar gets but also the biological mechanism by which the drug exerts its effect. The gene encoding inhibitory receptor cytotoxic Tlymphocyte protein 4 (CTLA4) is implicated in RA susceptibility owing to a disease associated risk variant in close proximity to this gene 25 . Abatacept, a CTLA4-Ig fusion protein that blocks costimulation of T cells, is an effective therapy for RA 71 . Carefully designed trials can therefore use genetic knowledge to better target the wide variety of available biologic therapies to the sub sets of patients most likely to respond. One of the major goals of genetic research is to facilitate the prescription of available drugs to those patients most likely to show the greatest benefit, with minimal off target effects. Large scale efforts are currently ongoing to genotype cohorts of patients at the onset of drugtherapy and gather pro spective data on their treatment response to determine whether genetics can aid initial treatment decisions 72, 73 .
Insights into gene regulation
From a molecular genetics standpoint, GWAS have provided important insights into the mechanisms of complex diseases. Somewhat surprisingly, perhaps, the vast majority of risk variants associated with rheumatic diseases, and indeed all complex diseases, are found outside traditional proteincoding regions 74 . Such var iants are unlikely to change the protein structure; they are perhaps more likely to affect the regulation of gene expression (in terms of the magnitude, response to stim ulation, celltype specificity or temporal pattern of gene expression).
Indeed, a wellrecognized finding from GWAS is the enrichment of diseaseassociated variants within cell typespecific regulatory regions 26, 74 . Although each cell in the body contains the same genetic material, the different combinations of genes actively expressed by different cell types determine the characteristics of those cells. Hence, diseaseassociated variants that map to regulatory regions might be responsible for controlling gene expression. Actively expressed genes typically reside in regions of DNA that are open and accessible, marked by histone modifications that enable this DNA to assume an unwound conformation. International efforts are now attempting to map these open, active regions of the genome in a range of cell types [75] [76] [77] [78] [79] [80] . For example, in T cells, DNA regions that are open and active are commonly enriched for risk variants associated with RA and JIA (in CD4 + T cells) 25, 81 , as well as with PsA (in CD8 + T cells) 37 . These findings confirm the implicit role of these cell types in disease and also highlight regions of the genome that are important in disease development, which often contain many plausible candidate genes.
One method for linking an associated risk variant to a causal gene is to look at its correlation with gene expression, in a technique known as expression quantita tive trait loci (eQTL) analysis [82] [83] [84] [85] [86] (TABLE 1) . This analysis has demonstrated compelling evidence that genes such as ERAP2, IRF5 and NCOA3 are regulated by variants Figure 3 | Genes of the T helper cell differentiation pathway implicated in rheumatic diseases. Pathway analysis of disease-associated genes has demonstrated that the T helper cell differentiation pathway has a key role in the pathogenesis of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS). Genes associated with at least one rheumatic disease are highlighted in pink, and labels next to these genes show with which disease(s) they are associated. Solid and dotted lines indicate direct or indirect relationships, respectively. Direct interactions (chemical modifications) require that two molecules make direct physical contact with each other, as opposed to indirect interactions that do not have this requirement. CD40L, CD40 ligand; CXCR5, C-X-C chemokine receptor type 5; FOXP3, forkhead box protein P3; GATA3, trans-acting T-cell-specific transcription factor GATA3; ICOS, inducible T cell co-stimulator; ICOSL, inducible T cell co-stimulator ligand; IFNγR, IFNγ receptor; IL-2R, IL-2 receptor; IL-4R, IL-4 receptor; IL-6R, IL-6 receptor; IL-10R, IL-10 receptor; IL-12R, IL-12 receptor; IL-21R, IL-21 receptor; RORγt, nuclear receptor RORγt; SHP2, tyrosine-protein phosphatase non-receptor type 11; STAT, signal transducer and activator of transcription; T-bet, T-box transcription factor TBX21; TCR, T cell receptor; T FH cell, T follicular helper cell; TGFβR, TGFβ receptor; T H cell, T helper cell; TNFR, TNF receptor; T reg cell, regulatory T cell.
◀ associated with AS 87, 88 , SLE 89 , and OA 22 , respectively. This type of correlation with genotype and expression has also revealed levels of mechanistic complexity for GWAS associated variants. For example, the correlation between genotype and expression is contextspecific, such that the majority of eQTLs are only revealed in certain cell types, under certain stimulatory conditions 84, 85 . Again, this find ing gives an insight into the mechanism by which genetic changes predispose to disease. Large international con sortia such as the Genotype-Tissue Expression (GTEx) project 82, 83, 90 are providing powerful data resources by mapping genotype and expression in a wealth of different tissues; these efforts should enable researchers to check whether a diseaseassociated variant can regulate gene expression in a particular cell type and/or condition.
When viewing DNA in a linear fashion, gene regula tory regions are often a large distance away from the genes they regulate; however, 3D conformational chromosomal structures enable regulatory regions to physically interact with distant genes. This physical interaction, and hence gene regulation, can occur over large distances, often 'skipping' the nearest gene. This distance can obviously complicate attempts to assign diseaseassociated variants to a gene, and might well have compromised postGWAS attempts at biological pathway analysis. Hence, future studies might yet reveal more subtle pathways to disease. These physical interactions can be revealed with molec ular biology techniques, fixing the DNA in its natural, 3D conformation, and then using sequencing to identify DNA regions that are in close proximity to each other. This type of DNA conformational analysis, including, for example, HiC 91, 92 (TABLE 1) for whole genome inter actions and chromosome conformation capture (3C) 93, 94 for local interactions, is beginning to add new interpre tations to findings from rheumatic disease GWAS. One experiment exploring the interactions of regions associ ated with RA, JIA and PsA revealed that the closest gene is not always the one interacting with the regulatory regions; interactions can span large genetic distances and DNA regions that contain variants associated with these diseases can interact with each other even if spa tially distinct 95 . For example, an RAassociated variant within the gene COG6 interacts with the gene promoter of FOXO1, which is, although sited some distance away, a much more compelling putative causal gene; COG6 encodes a component of Golgi apparatus whereas FOXO1 encodes a transcription factor important in the survival of fibroblastlike synoviocytes (FLS) in RA 96 and is hyper methylated in FLS from patients with RA compared with FLS from patients with OA 97 . In addition, by use of 3C analysis, another study demonstrated that a region down stream of TNFAIP3, which contains a DNA insertion associated with SLE, interacts with the TNFAIP3 pro moter, supporting the causal role of this gene 98, 99 . Thus, these types of experiments are beginning to provide great insight into celltypespecific and genotypespecific reg ulatory interactions, and demonstrate the complexity of gene regulation.
Conclusions
As is so often the case in scientific research, investigations into the genetic basis of rheumatic diseases have revealed more questions than they have answered. Although for many conditions we have considerably increased our knowledge of genetic associations with disease in the past 10 years, we have in turn discovered that we can not assume associated variants affect the function of their nearest gene. Unravelling the function of disease associated variants will require an increased understand ing of how gene expression is regulated. Elucidating the genetic basis of disease continues to hold great promise and, as illustrated here, this challenge is ongoing. Current insights are close to influencing the treatment of patients with rheumatic diseases through the identification of new drugs, repositioning of existing therapies and a stratified medicine approach to treatment selection.
In the past two years, exponential advances in genetic engineering, specifically in the form of CRISPR-Cas9 genome editing [100] [101] [102] (TABLE 1) , have enabled researchers to ask morespecific questions, such as how disease associated alleles affect the process of complex diseases. Although beyond the scope of this Review, genome edit ing technology will probably provide robust, empirical evidence of the mechanism(s) by which these genetic components influence disease. For example, gene regulators, DNA variants and whole pathways can be precisely perturbed using genome editing to determine their downstream phenotypic consequences [103] [104] [105] [106] . By precisely manipulating the genetic background of a cell from nonrisk to risk, or by targeting the implicated regulators, researchers can gain further insight into these complex diseases.
